COVID-19 Clinical Research Studies

The paper describes a biobanking initiative collecting genetic and clinical data from over 1,000 SARS-CoV-2-positive individuals to study multi-organ involvement and genetic factors in COVID-19 severity.

This study uses single-cell RNA sequencing to analyze Tocilizumab-treated PBMCs, showing reduced inflammatory gene expression in monocytes, supporting its potential to mitigate cytokine storms in COVID-19.

This study identifies 91 differentially expressed plasma proteins between severe and non-severe COVID-19 patients, highlighting potential biomarkers and therapeutic targets.

The paper identifies molecular signatures and dysregulated pathways in COVID-19 patients with varying disease severity using transcriptome sequencing of nasopharyngeal swabs.

This study uses Mendelian randomization to show that genetically proxied IL-6 signaling inhibition reduces COVID-19 risk but increases pneumonia risk.

The paper reports Whole Exome Sequencing analysis of 35 hospitalized COVID-19 patients, identifying pathogenic mutations linked to virus infection susceptibility and disease progression.

The paper uses single-cell analysis to show that Tocilizumab reduces monocyte-driven inflammation in severe COVID-19 but does not fully suppress immune responses.

The paper investigates the association between ApoE e4 genotype and severe COVID-19 in the UK Biobank community cohort, finding a link with increased risk of severe outcomes.

The paper examines sex differences in ACE2 and TMPRSS2 expression in prostate and lung epithelial cells, finding higher ACE2 expression in male lung type II pneumocytes and co-expression in prostate club cells.